Local drug delivery systems and prevention of restenosis

Cardiovascular Research

Volumn 35, Issue 3, 1997, Pages 405-413

  Brieger, David ^a   Topol, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Percutaneous coronary revascularization; Restenosis

Indexed keywords

VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DEVICE; DRUG DELIVERY SYSTEM; GENE TRANSFER; HEART MUSCLE REVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BALLOON DILATATION; BLOOD VESSEL PROSTHESIS; CORONARY DISEASE; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEPARIN; HUMANS; RECURRENCE;

EID: 0030785344     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00155-7     Document Type: Review

References (64)

1. Franklin SM, Faxon DP Pharmacologic prevention of restenosis after coronary angioplasty: Review of randomized clinical trials. Coronary Artery Dis. 4:1993;232-242.
2. Glagov S Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 89:1994;2888-2891.
3. Scott NA, Cipolla GD, Ross CEet al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 93:1996;2178-2187.
4. Hoffmann R, Mintz GS, Dussaillant GRet al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation. 94:1996;1247-1254.
5. Serruys PW, de Jaegere P, Kiemeneij Fet al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
6. Fischman DL, Leon MB, Baim DSet al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
7. Lehmann KG, Doria RJ, Feuer JMet al. Paradoxical increase in restenosis rate with chronic heparin use: Final results of a randomized trial. J Am Coll Cardiol. 17:1991;181A. abstract.
8. Ellis SG, Roubin GS, Wilentz Jet al. Effect of 18- to 24-hour heparin administration for the prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 117:1989;777-782.
9. Edelman ER, Karnovsky MJ Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation. 89:1993;770-776.
10. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 93:1994;1243-1249.
11. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
12. Jorgenson B, Tonnesen KH, Bulow Jet al. Femoral artery recanalization with percutaneous angioplasty and segmentally enclosed plasminogen activator. Lancet. 1:1989;1106-1108.
13. Goldman B, Blanke H, Wolinsky H Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. Atherosclerosis. 65:1987;215-225.
14. Nabel EG, Plautz G, Nabel GJ Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 249:1990;1285-1288.
15. Wolinsky H, Thung SN Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 15:1990;475-481.
16. Lambert CR, Leone JE, Rowland SM Local drug delivery catheters: Functional comparison of porous and microporous designs. Cor Art Dis. 4:1993;469-475.
17. Stadius ML, Collins C, Kernoff R Local infusion balloon angioplasty to obviate restenosis compared with conventional balloon angioplasty in an experimental model of atherosclerosis. Am Heart J. 126:1993;47-56.
18. Santoian EC, Gravanis MB, Schneider JEet al. Use of the porous balloon in porcine coronary arteries: rationale for low pressure and volume delivery. Catheter Cardiovasc Diagn. 30:1993;348-354.
19. Hong MK, Wong SC, Farb Aet al. Feasibility and drug delivery efficacy of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Cor Art Dis. 4:1993;1023-1207.
20. Cumberland DC, Gunn J, Tsikaderis D, Arafa S, Ahsan A Initial clinical experience of local drug delivery via a porous balloon during percutaneous coronary angioplasty. J Am Coll Cardiol. 23:1994;186A. abstract.
21. Kaplan AV, Kermode J, Grant Get al. Intramural delivery of marker agent in ex vivo and in vivo models using a novel drug delivery sleeve. J Am Coll Cardiol. 23:1994;187A. abstract.
22. Fram DB, Aretz TA, Azrin MAet al. Localized intramural drug delivery during balloon angioplasty using hydrogel coated balloons and pressure-augmented diffusion. J Am Coll Cardiol. 23:1994;1570-1577.
23. Hong MK, Wong SC, Popma JJet al. A dual-purpose angioplasty-drug infusion catheter for the treatment of intragraft thrombus. Cath Cardiovasc Diagn. 32:1994;193-195.
24. Fernandez-Ortiz A, Meyer BJ, Mailhac Aet al. A new approach for local intravascular drug delivery: Iontophoretic balloon. Circulation. 89:1994;1518-1522.
25. Hofling B, Huehns TY Clinical Perspective. Intravascular local drug delivery after angioplasty. Eur Heart J. 16:1995;437-440.
26. Thomas CN, Robinson KA, Cipolla GD, Jones M, King SB, Scott NA In-vivo delivery of heparin to coronary arteries with a microporous infusion catheter. J Am Coll Cardiol. 23:1994;187A. abstract.
27. Wilensky RL, March KL, Gradus-Pizlo Iet al. Regional and arterial localization of radioactive microparticles after local delivery by unsupported and supported porous balloon catheters. Am Heart J. 129:1995;852-859.
28. Fram DB, Mitchel JF, Eldin AM, Waters DD, Norenberg FW, McKay RG Intramural delivery of 3H-heparin with a new site-specific drug delivery system: The D3 catheter. J Am Coll Cardiol. 23:1994;186A. abstract.
29. Dev V, Zeng H, Forrester Jet al. Microspheres for drug delivery in the arterial wall: a study of kinetic, toxicity, and effect of corticosteroid loaded microspheres. J Am Coll Cardiol. 88(I):1994;310. abstract.
30. Guzman LA, Labhasetwar V, Song Cet al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation. 94:1996;1441-1448.
31. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 73:1993;797-807.
32. Willard JE, Jessen ME, Gerard RDet al. Recombinant adenovirus is an efficient vector for in vivo gene transfer and can be preferentially directed at vascular endothelium or smooth muscle cells. Circulation. 86(I):1992;473. abstract.
33. Maillard L, Walsh K Growth-arrest homeobox gene Gax: A molecular strategy to prevent arterial restenosis. Schweiz Med Wochenschr. 126:1996;1721-1726.
34. Chang MW, Barr E, Lu M, Barton K, Leiden JM Adenovirus mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointimal formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 96:1995;2260-2268.
35. Chang MW, Ohno T, Gordon Det al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation an neointima formation following balloon angioplasty of the rat carotid artery. Mol Med. 1:1995;172-181.
36. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of herpes simplex thymidine kinase gene. Proc Natl Acad Sci USA. 91:1994;10732-10736.
37. Chang MW, Barr E, Seltzer J-Qet al. Cytostatic gene therapy for vascular proliferative disorders using a constitutively active form of Rb. Science. 267:1994;518-522.
38. Neve RL Adenovirus vectors enter the brain. Trends Neurosci. 16:1993;251-253.
39. Herz J, Gerard RD Adenovirus-mediated transfer of low density lipoprotein gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 90:1993;2812-2816.
40. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 91:1994;4407-4411.
41. Engelhardt JF, Ye X, Doranz B, Wilson JM Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory responses in mouse liver. Proc Natl Acad Sci USA. 91:1994;6196-6200.
42. Morishita R, Gibbons G, Kaneda Y, Ogihara T, Dzau VJ Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. Hypertension. 21:1993;894-899.
43. von der Leyen HE, Gibbons GH, Morishita Ret al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
44. Plautz G, Nabel EG, Nabel GJ Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation. 83:1991;578-583.
45. Simons M, Edelman ER, Rosenberg RD Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest. 93:1994;2351-2356.
46. Morishita R, Gibbons GH, Ellison KEet al. Single intraluminal delivery of antisense CDC2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 90:1993;8474-8478.
47. Bennett MR, Anglin S, McEwan JRet al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 93:1994;8294-8298.
48. Burgess TL, Fisher EF, Ross SLet al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA. 92:1995;4051-4055.
49. van der Giessen WJ, Lincoff M, Schwartz RSet al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94:1996;1690-1697.
50. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR Percutaneous polymeric stents in porcine coronary arteries: Initial experience with polyethylene terephthalate stents. Circulation. 86:1992;1596-1604.
51. Baker JE, Nikolaychik V, Zulich Aet al. Fibrin coated stents as a depot to deliver RGD peptide inhibit vascular reaction in atherosclerotic rabbit model. J Am Coll Cardiol. 27:1996;197A. abstract.
52. Lincoff AM, Furst JG, Ellis SE, Topol EJ Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery. J Am Coll Cardiol. 23:1994;18A. abstract.
53. Hardhammer PA, Van Beusekom H, Emanuelsson HVet al. Reduction of thrombotic events using heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation. 93:1996;423-430.
54. Serruys PW, Emanuelsson H, van der Giessen Wet al. Heparin-coated palmaz-schatz stents in human coronary arteries. Early outcome of the Benestent-II pilot study. Circulation. 93:1996;412-422.
55. Williams DO Dressing up the Palmaz-Schatz stent. Circulation. 93:1996;400-402.
56. Lambert TL, Dev V, Rechavia Eet al. Localized arterial wall drug delivery from a polymer coated removable metallic stent; kinetics, distribution, and bioactivity of forskolin. Circulation. 90:1994;1003-1011.
57. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF Seeding of intravascular stents with genetically engineered endothelial cells. Circulation. 80:1989;1347-1353.
58. Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation. 91:1995;1533-1539.
59. Verin V, Popowski Y, Urban Pet al. Intra-arterial beta irradiation prevents a neointimal hyperplasia in a hypercholesterolemic rabbit restenosis model. Circulation. 92:1995;2284-2290.
60. Waksman R, Robinson KA, Crocker IRet al. Intracoronary radiation before stent implantation inhibits neointima formation in stented porcine coronary arteries. Circulation. 92:1995;1383-1386.
61. van der Giessen WJ, Serruys PW B-particle-emitting stents radiate enthusiasm in the search for effective prevention of restenosis. Circulation. 94:1996;2358-2360.
62. Carter AJ, Laird JR, Bailey LRet al. Effects of endovascular radiation from a B-particle-emitting stent in a porcine coronary restenosis model: A dose response study. Circulation. 94:1996;2364-2368.
63. Hehrlein C, Stintz M, Kinscherf Ret al. Pure B-particle emitting stents inhibit neointima formation in rabbits. Circulation. 93:1996;641-645.
64. Laird JR, Carter AJ, Kufs WMet al. Inhibition of neointimal proliferation with low-dose irradiation from a B-particle-emitting stent. Circulation. 93:1996;529-536.